We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Marker for Unfavorable Leukemia Prognosis

By Biotechdaily staff writers
Posted on 23 May 2002
Genetic testing for an enzyme involved in cancer-cell proliferation could identify patients at an increased risk of poor outcome from acute lymphoblastic leukemia.

A research letter in the March 23, 2002, issue of The Lancet reports that the enzyme thymidylate synthase is associated with cell proliferation, and is therefore an important target for anticancer drugs, including the chemotherapeutic agent methotrexate. More...
The letter's author, Dr. Maja Krajinovic, from the University of Montreal, (Canada), and colleagues investigated the possible association between a variant of the gene coding for thymidylate synthase--in which a specific triple repeat alteration is associated with increased expression of thymidylate synthase--and the outcome of acute lymphoblastic leukemia in 205 children treated with methotrexate.

DNA samples from patients were analyzed for variation by polymerase chain reaction (PCR) amplification. The results showed that children who were homozygous for the triple repeat were four times more likely to have a poorer outcome than children with other genotypes.

Dr. Krajinovic comments: "Thymidylate synthase genotype seems to be a significant predictor of outcome in childhood acute lymphoblastic leukemia. This finding could lead to individualization of treatment for patients with this disease.”




Related Links:
University of Montreal

Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
New
Gold Member
POC Helicobacter Pylori Test Kit
Hepy Urease Test
CMV CLIA Diagnostic
CLIA CMV IgA Screen Group
Japanese Encephalitis Test
Japanese Encephalitis Virus Real Time PCR Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Alzheimer’s pathology can start 15 to 20 years before symptoms, and validated tools that reach patients earlier help pave the way for earlier detection. (Image Credit: Adobe Stock)

Alzheimer’s Blood Test Becomes First FDA-Cleared Option for Adults as Young as 40

C2N Diagnostics’ PrecivityAD2 blood test was cleared by the U.S. Food and Drug Administration (FDA) on August 20, 2026, for adults as young as 40 who are experiencing signs of cognitive impairment, according... Read more

Pathology

view channel
Image: Adrenal gland tumor stained with hematoxylin and eosin (top) and CYP11B2 (bottom) (Photo courtesy of Christofer Juhlin)

Simple Immunohistochemical Size Ratio Improves Classification of Primary Aldosteronism

Primary aldosteronism is a common but underdiagnosed cause of hypertension, in which excess aldosterone promotes salt retention and raises blood pressure. Identifying the dominant source of hormone overproduction... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.